The 12 Biomarkers Every High-Performer Should Track Annually

ApoB is the protein that coats every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Each particle carries exactly one ApoB molecule, making ApoB a direct count of the number of atherogenic particles in your bloodstream. Multiple large-scale studies have confirmed that ApoB is a superior predictor of cardiovascular events compared to LDL cholesterol. A person with small, dense LDL particles can have a "normal" LDL of 110 mg/dL but an ApoB of 130 mg/dL — indicating three times the cardiovascular risk their LDL suggests.

Lp(a) is a genetically determined lipoprotein that carries both atherogenic and thrombogenic risk. Elevated Lp(a) — present in approximately 20% of the population — is an independent risk factor for heart attack, stroke, and aortic stenosis that is not captured by standard lipid panels. Unlike LDL, Lp(a) cannot be significantly lowered by diet or exercise; it requires specific pharmacological interventions. Knowing your Lp(a) level is essential for accurate cardiovascular risk stratification.

Fasting insulin is the earliest and most sensitive marker of insulin resistance — the metabolic dysfunction that underlies type 2 diabetes, metabolic syndrome, cardiovascular disease, and accelerated aging. Fasting glucose can remain normal for years while insulin resistance is developing, because the pancreas compensates by producing more insulin. By the time fasting glucose is elevated, significant metabolic damage has already occurred. Fasting insulin below 5 µIU/mL indicates excellent insulin sensitivity; levels above 10 µIU/mL suggest significant resistance.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is calculated from fasting insulin and fasting glucose: (fasting insulin × fasting glucose) / 405. It provides a more complete picture of insulin resistance than either marker alone. A HOMA-IR below 1.0 indicates excellent insulin sensitivity; above 2.0 suggests significant resistance; above 3.0 indicates severe insulin resistance with high risk of type 2 diabetes and metabolic syndrome.

High-sensitivity CRP is the most validated blood marker of systemic inflammation and a powerful independent predictor of cardiovascular events. The JUPITER trial demonstrated that statin therapy reduced cardiovascular events in people with normal LDL but elevated hs-CRP — confirming that inflammation, not just cholesterol, drives atherosclerosis. Chronically elevated hs-CRP is also associated with accelerated biological aging, cognitive decline, and increased cancer risk. Optimal levels are below 0.5 mg/L; levels above 3.0 mg/L indicate high cardiovascular risk.

Homocysteine is an amino acid produced during methionine metabolism. Elevated homocysteine damages the endothelial lining of blood vessels, promotes oxidative stress, and is associated with increased risk of cardiovascular disease, stroke, cognitive decline, and Alzheimer's disease. It is also a marker of impaired methylation — a critical cellular process involved in DNA repair, neurotransmitter synthesis, and detoxification. Elevated homocysteine is almost always correctable with B12, folate, and B6 supplementation.

Free testosterone — the biologically active fraction not bound to SHBG — is the most clinically relevant testosterone marker for assessing hormonal health. Total testosterone can be misleading if SHBG is elevated. Free testosterone below the upper quartile of the age-matched reference range is associated with fatigue, reduced muscle mass, cognitive decline, low libido, and increased cardiovascular risk. Tracking free testosterone annually allows early detection of hormonal decline and timely intervention.

IGF-1 is the primary mediator of growth hormone's anabolic effects and a key regulator of cellular growth, repair, and metabolism. Both very low and very high IGF-1 are associated with increased mortality — low levels with sarcopenia, cognitive decline, and cardiovascular disease; high levels with increased cancer risk. The optimal range is the upper-middle quartile for age — high enough to maintain anabolic function, low enough to avoid oncogenic signaling.

DHEA-S is the most abundant circulating steroid hormone and a precursor to both testosterone and estrogen. It declines dramatically with age — by 80, most people have less than 20% of their peak DHEA-S levels. Low DHEA-S is associated with increased cardiovascular risk, immune dysfunction, cognitive decline, and reduced quality of life. It is also a reliable marker of adrenal reserve and overall hormonal vitality. DHEA supplementation has demonstrated benefits for bone density, immune function, and mood in multiple clinical trials.

Vitamin D is not merely a vitamin — it is a steroid hormone that regulates over 1,000 genes involved in immune function, inflammation, calcium metabolism, insulin sensitivity, and cardiovascular health. Deficiency (below 30 ng/mL) is associated with increased risk of autoimmune disease, cancer, cardiovascular disease, type 2 diabetes, and all-cause mortality. The optimal range for longevity is 60–80 ng/mL — significantly higher than the "sufficient" threshold of 30 ng/mL used in standard medicine.

The Omega-3 Index measures the percentage of EPA and DHA in red blood cell membranes — a reliable indicator of long-term omega-3 status. An Omega-3 Index above 8% is associated with a 90% reduction in sudden cardiac death risk compared to an index below 4%. Omega-3 fatty acids reduce triglycerides, lower inflammatory markers, improve endothelial function, and have demonstrated benefits for cognitive health, depression, and longevity. Most Americans have an Omega-3 Index of 4–5% — well below optimal.

HbA1c reflects average blood glucose over the preceding 2–3 months by measuring the percentage of hemoglobin that has been glycated (sugar-coated). While standard medicine considers HbA1c below 5.7% "normal," longevity research suggests that optimal levels for minimizing aging and disease risk are below 5.3%. Even within the "normal" range, each 0.1% increase in HbA1c above 5.0% is associated with measurable increases in cardiovascular risk, cognitive decline, and all-cause mortality.